Business Context and Reporting Period
This Form 10-K is filed by Brooks Automation, Inc. for the fiscal year ended September 30, 2017; the request identifies the company as Azenta, Inc., so the issuer-name change should be verified. The company provides semiconductor automation, vacuum, contamination-control and cryogenic solutions, and life-science sample-management products and services.
Fiscal 2017 revenue was generated approximately 79% by Brooks Semiconductor Solutions Group and 21% by Brooks Life Science Systems. The filing reports fourth-quarter fiscal 2017 revenue of $181.9 million, gross profit of $74.4 million, operating income of $17.4 million and net income of $17.4 million.
Financial Performance and Liquidity
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Revenue | $692.9 million | $560.3 million | Up 24% |
| Gross profit | $267.4 million | $198.1 million | Up $69.3 million |
| Gross margin | 38.6% | 35.4% | Up 3.2 percentage points |
| Operating income | $64.1 million | $4.2 million | Up $59.9 million |
| Operating margin | 9.3% | 0.8% | Improved |
| Net income (loss) | $62.6 million | $(69.5) million | Returned to profitability |
| Diluted EPS | $0.89 | $(1.01) | Improved |
| Cash flow from operations | $96.2 million | $39.5 million | Up $56.7 million |
- Semiconductor Solutions revenue was $544.2 million, up 20%; Life Science Systems revenue was $148.7 million, up 38%, including $25.3 million of organic growth.
- Research and development expense declined to $47.0 million from $51.5 million, while selling, general and administrative expense increased to $153.1 million from $130.3 million.
- Cash, cash equivalents and marketable securities totaled $104.3 million at September 30, 2017, including $101.6 million of cash and $2.7 million of marketable securities. Working capital was $100.9 million.
- Capital expenditures were $12.7 million, acquisition cash payments were $44.8 million, and cash dividends paid were $27.9 million.
- The company had no borrowings under its $75.0 million revolving credit facility and approximately $45.1 million of availability at September 30, 2017.
- Goodwill was $233.6 million and net intangible assets were $83.5 million. No goodwill impairment was recorded.
Material Changes Versus the Prior Comparable Period
- Revenue growth occurred in both segments, supported by stronger semiconductor demand, contamination-control and cryogenic products, life-science storage services, automated storage systems, consumables and instruments.
- Gross-margin expansion reflected operating leverage, product-cost optimization, lower repair-material costs, restructuring savings and improved execution on large life-science projects.
- Operating results benefited from restructuring savings and lower restructuring charges of $3.2 million versus $12.0 million in fiscal 2016.
- The fiscal 2016 net loss included a largely non-cash $79.3 million increase in the valuation allowance against U.S. deferred tax assets. Fiscal 2017 income tax expense declined to $12.1 million from $75.8 million; the full U.S. valuation allowance remained in place.
- Fiscal 2017 acquisitions included Cool Lab, Pacific Bio-Material Management and Novare, and selected RURO assets related to FreezerPro. These transactions added $31.5 million of goodwill and expanded life-science cold-chain and informatics capabilities.
- Backlog increased to approximately $115 million in Semiconductor Solutions from $92 million and to $250 million in Life Science Systems from $233 million.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide specific numerical revenue, earnings or margin guidance. Management expects continued semiconductor-market opportunities but notes that semiconductor capital-equipment demand is cyclical and quarterly product revenue can vary by 10% to 20%. Management also expects longer-term growth from life-science sample management, storage services, consumables, instruments and informatics.
- On October 4, 2017, after year-end, the company entered into a $200.0 million senior secured term loan, issued at a $2.4 million discount. The loan matures October 4, 2024, bears variable interest, is secured by substantially all assets and has excess-cash-flow repayment provisions beginning December 2018.
- On October 5, 2017, the company acquired 4titude Limited for $65.5 million net of cash acquired. Purchase accounting was incomplete at the filing date.
- The company maintains a full valuation allowance against U.S. deferred tax assets despite reaching cumulative U.S. pretax profitability, citing cyclical semiconductor exposure and expected interest costs from new debt.
- Key risks include semiconductor cyclicality, customer concentration, competitive and pricing pressure, foreign-exchange exposure, acquisition integration, supply-chain and manufacturing disruptions, sample-storage facility failures, cybersecurity, intellectual-property claims, goodwill impairment, variable-rate debt and covenant or liquidity risk.
- Top ten customers represented approximately 39% of fiscal 2017 revenue, although no individual customer exceeded 10%.
- Contractual cash obligations totaled approximately $155.0 million, plus $3.5 million of letters of credit. The filing states that no material legal proceeding was expected to adversely affect consolidated results, but outcomes remain uncertain.
Important Facts for Investors to Verify
- Confirm the relationship between the Brooks Automation filing and the requested Azenta, Inc. issuer identity.
- Reconcile fiscal fourth-quarter results with the full-year financial statements and assess whether sequential growth reflects sustainable demand or semiconductor-cycle timing.
- Evaluate the effect of the post-year-end $200.0 million term loan, including interest expense, leverage, collateral and excess-cash-flow repayment requirements.
- Review the completed purchase accounting and subsequent contribution of 4titude, as well as integration performance for the fiscal 2017 acquisitions.
- Monitor realization of restructuring savings, gross-margin sustainability and the continued full valuation allowance on U.S. deferred tax assets.
- Assess backlog quality, expected delivery timing and the proportion attributable to products, services and long-term life-science storage contracts.